Search

Meet Antonio Almeida, our February Volunteer of the Month

EHA is a Public Benefit Organization under Dutch law.

Read more

Registration & accommodation

Registration will open soon

Individual registrationIn-person registration fee includes:

Access to the scientific and educational sessions of the meeting
Networking opportunities to speak with the faculty during breaks and the welcome reception
Coffee/tea breaks and lunches on April 25 and 26 
Access to the poster…

Read more

Enabling the spread of good research – a day in the life of an Editor-in-Chief

Most conversations with the Editor of a scientific journal usually revolve around the acceptance (hooray!) or rejection (oh no!) of our research work.

Read more

EHA Guidelines by Topic

AL Amyloidosis
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines (2021)
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group (2022)
Anemia
Recommendations regarding splenectomy in hereditary hemolytic anemias (2017)
Management of…

Read more

Collaboration with the EMA on Joint Clinical Assessments and Joint Scientific Consultations under the HTA Regulation

The European Hematology Association (EHA) welcomes the draft Implementing Act laying down procedural rules for the exchange of information between the Health Technology Assessment (HTA) Coordination Group, the European Commission, and the European Medicines Agency (EMA).

Read more

Training vital for new era of patient-centric healthcare

Christine Chomienne, president of the European Hematology Association (EHA), was speaking at the third annual conference of the European Alliance for Personalised Medicine (EAPM) – a Brussels-based organization that brings together stakeholders from academia, through research,…

Read more

Helping to shape Europe’s clinical trials landscape: EHA selected for ACT EU advisory group

Improving the design, efficiency and effectiveness of clinical trials is the objective of the Accelerating Clinical Trials in the European Union (ACT EU) initiative.

Read more